

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 2.3 mg hard capsules
NINLARO 3 mg hard capsules
NINLARO 4 mg hard capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NINLARO 2.3 mg hard capsules

Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate)

NINLARO 3 mg hard capsules

Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate)

NINLARO 4 mg hard capsules

Each capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib citrate)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Hard capsule.

NINLARO 2.3 mg hard capsules

Light pink, size 4 gelatin hard capsule, marked “Takeda” on the cap and “2.3 mg” on the body with black ink.

NINLARO 3 mg hard capsules

Light grey, size 4 gelatin hard capsule, marked “Takeda” on the cap and “3 mg” on the body with black ink.

NINLARO 4 mg hard capsules

Light orange, size 3 gelatin hard capsule, marked “Takeda” on the cap and “4 mg” on the body with black ink.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

4.2 Posology and method of administration

Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma.

Posology

The recommended starting dose of ixazomib is 4 mg administered orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle.

The recommended starting dose of lenalidomide is 25 mg administered daily on Days 1 to 21 of a 28-day treatment cycle.

The recommended starting dose of dexamethasone is 40 mg administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle.

Dosing schedule: Ixazomib taken with lenalidomide and dexamethasone

| 28-day cycle (a 4-week cycle) | | | | | | | | |
|-------------------------------|--------|-------------|--------|--------------|--------|---------------|--------|---------------|
| | Week 1 | | Week 2 | | Week 3 | | Week 4 | |
| | Day 1 | Days 2 to 7 | Day 8 | Days 9 to 14 | Day 15 | Days 16 to 21 | Day 22 | Days 23 to 28 |
| Ixazomib | ✓ | | ✓ | | ✓ | | | |
| Lenalidomide | ✓ | ✓ Daily | ✓ | ✓ Daily | ✓ | ✓ Daily | | |
| Dexamethasone | ✓ | | ✓ | | ✓ | | ✓ | |

✓ = intake of medicinal product

For additional information regarding lenalidomide and dexamethasone, refer to the Summary of Product Characteristics (SmPC) for these medicinal products.

Prior to initiating a new cycle of therapy:

- Absolute neutrophil count should be $\geq 1\,000/\text{mm}^3$
- Platelet count should be $\geq 75\,000/\text{mm}^3$
- Non-haematologic toxicities should, at the physician's discretion, generally be recovered to patient's baseline condition or \leq Grade 1

Treatment should be continued until disease progression or unacceptable toxicity. Treatment with ixazomib in combination with lenalidomide and dexamethasone for longer than 24 cycles should be based on an individual benefit risk assessment, as the data on the tolerability and toxicity beyond 24 cycles are limited (see section 5.1).

Delayed or missed doses

In the event that a ixazomib dose is delayed or missed, the dose should be taken only if the next scheduled dose is ≥ 72 hours away. A missed dose should not be taken within 72 hours of the next scheduled dose. A double dose should not be taken to make up for a missed dose.

If a patient vomits after taking a dose, the patient should not repeat the dose but should resume dosing at the time of the next scheduled dose.

Dose modifications

The ixazomib dose reduction steps are presented in Table 1 and the dose modification guidelines are provided in Table 2.

Table 1: Ixazomib dose reduction steps

| Recommended starting dose* | First reduction to | Second reduction to | Discontinue |
|----------------------------|--------------------|---------------------|-------------|
| 4 mg | 3 mg | 2.3 mg | |

*Recommended reduced dose of 3 mg in the presence of moderate or severe hepatic impairment, severe renal impairment or end-stage renal disease (ESRD) requiring dialysis.

An alternating dose modification approach is recommended for ixazomib and lenalidomide for overlapping toxicities of thrombocytopenia, neutropenia and rash. For these toxicities, the first dose modification step is to withhold/reduce lenalidomide. Refer to the lenalidomide SmPC, section 4.2 for the dose reduction steps for these toxicities.

Table 2: Dose modifications guidelines for ixazomib in combination with lenalidomide and dexamethasone

| Haematological toxicities | Recommended actions |
|--|---|
| Thrombocytopenia (platelet count) | |
| Platelet count < 30 000/mm ³ | <ul style="list-style-type: none"> Withhold ixazomib and lenalidomide until platelet count \geq 30 000/mm³. Following recovery, resume lenalidomide at the next lower dose according to its SmPC and resume ixazomib at its most recent dose. If platelet count falls to < 30 000/mm³ again, withhold ixazomib and lenalidomide until platelet count \geq 30 000/mm³. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its most recent dose.* |
| Neutropenia (absolute neutrophil count) | |
| Absolute neutrophil count < 500/mm ³ | <ul style="list-style-type: none"> Withhold ixazomib and lenalidomide until absolute neutrophil count is \geq 500/mm³. Consider adding G-CSF as per clinical guidelines. Following recovery, resume lenalidomide at the next lower dose according to its prescribing information and resume ixazomib at its most recent dose. If absolute neutrophil count falls to < 500/mm³ again, withhold ixazomib and lenalidomide until absolute neutrophil count is \geq 500/mm³. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its most recent dose.* |
| Non-haematological toxicities | |
| Rash | |
| Grade [†] 2 or 3 | <ul style="list-style-type: none"> Withhold lenalidomide until rash recovers to \leq Grade 1. Following recovery, resume lenalidomide at the next lower dose according to its SmPC. If Grade 2 or 3 rash occurs again, withhold ixazomib and lenalidomide until rash recovers to \leq Grade 1. Following recovery, resume ixazomib at the next lower dose and resume lenalidomide at its most recent dose.* |
| Grade 4 | Discontinue treatment regimen. |
| Peripheral neuropathy | |
| Grade 1 peripheral neuropathy with pain or Grade 2 peripheral neuropathy | <ul style="list-style-type: none"> Withhold ixazomib until peripheral neuropathy recovers to \leq Grade 1 without pain or patient's baseline. Following recovery, resume ixazomib at its most recent dose. |
| Grade 2 peripheral neuropathy with pain or Grade 3 peripheral neuropathy | <ul style="list-style-type: none"> Withhold ixazomib. Toxicities should, at the physician's discretion, generally recover to patient's baseline condition or \leq Grade 1 prior to resuming ixazomib. Following recovery, resume ixazomib at the next lower dose. |
| Grade 4 peripheral neuropathy | Discontinue treatment regimen. |

Table 2: Dose modifications guidelines for ixazomib in combination with lenalidomide and dexamethasone

| Other non-haematological toxicities | |
|--|--|
| Other Grade 3 or 4 non-haematological toxicities | <ul style="list-style-type: none"> • Withhold ixazomib. Toxicities should, at the physician’s discretion, generally recover to patient’s baseline condition or at most Grade 1 prior to resuming ixazomib. • If attributable to ixazomib, resume ixazomib at the next lower dose following recovery. |

*For additional occurrences, alternate dose modification of lenalidomide and ixazomib

†Grading based on National Cancer Institute Common Terminology Criteria (CTCAE) Version 4.03

Concomitant medicinal products

Antiviral prophylaxis should be considered in patients being treated with ixazomib to decrease the risk of herpes zoster reactivation. Patients included in studies with ixazomib who received antiviral prophylaxis had a lower incidence of herpes zoster infection compared to patients who did not receive prophylaxis.

Thromboprophylaxis is recommended in patients being treated with ixazomib in combination with lenalidomide and dexamethasone, and should be based on an assessment of the patient’s underlying risks and clinical status.

For other concomitant medicinal products that may be required, refer to the current lenalidomide and dexamethasone SmPC.

Special patient populations

Elderly

No dose adjustment of ixazomib is required for patients over 65 years of age.

Discontinuations in patients > 75 years of age were reported in 13 patients (28%) in the ixazomib regimen and 10 patients (16%) in the placebo regimen. Cardiac arrhythmias in patients > 75 years of age were observed in 10 patients (21%) in the ixazomib regimen and 9 patients (15%) in the placebo regimen.

Hepatic impairment

No dose adjustment of ixazomib is required for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or total bilirubin > 1-1.5 x ULN and any AST). The reduced dose of 3 mg is recommended in patients with moderate (total bilirubin > 1.5-3 x ULN) or severe (total bilirubin > 3 x ULN) hepatic impairment (see section 5.2).

Renal impairment

No dose adjustment of ixazomib is required for patients with mild or moderate renal impairment (creatinine clearance ≥ 30 mL/min). The reduced dose of 3 mg is recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min) or end-stage renal disease (ESRD) requiring dialysis. Ixazomib is not dialyzable and, therefore, can be administered without regard to the timing of dialysis (see section 5.2).

Refer to the lenalidomide SmPC for dosing recommendations in patients with renal impairment.

Paediatric population

The safety and efficacy of ixazomib in children below 18 years of age have not been established. No data are available.

Method of administration

Ixazomib is for oral use.

Ixazomib should be taken at approximately the same time on Days 1, 8, and 15 of each treatment cycle at least 1 hour before or at least 2 hours after food (see section 5.2). The capsule should be swallowed whole with water. It should not be crushed, chewed, or opened (see section 6.6).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional contraindications.

4.4 Special warnings and precautions for use

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional special warnings and precautions for use.

Thrombocytopenia

Thrombocytopenia has been reported with ixazomib (see section 4.8) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle (see section 4.8).

Platelet counts should be monitored at least monthly during ixazomib treatment. More frequent monitoring should be considered during the first three cycles as per the lenalidomide SmPC. Thrombocytopenia can be managed with dose modifications (see section 4.2) and platelet transfusions as per standard medical guidelines.

Gastrointestinal toxicities

Diarrhoea, constipation, nausea and vomiting have been reported with ixazomib, occasionally requiring use of antiemetic and antidiarrhoeal medicinal products and supportive care (see section 4.8). The dose should be adjusted for severe (Grade 3-4) symptoms (see section 4.2). In case of severe gastrointestinal events, monitoring of serum potassium level is recommended.

Peripheral neuropathy

Peripheral neuropathy has been reported with ixazomib (see section 4.8). The patient should be monitored for symptoms of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy may require dose modification (see section 4.2).

Peripheral oedema

Peripheral oedema has been reported with ixazomib (see section 4.8). The patient should be evaluated for underlying causes and provide supportive care, as necessary. The dose of dexamethasone should be adjusted per its prescribing information or ixazomib for Grade 3 or 4 symptoms (see section 4.2).

Cutaneous reactions

Rash has been reported with ixazomib (see section 4.8). Rash should be managed with supportive care or with dose modification if Grade 2 or higher (see section 4.2). Severe cutaneous adverse reactions (SCARs) including Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, have also been rarely reported in association with ixazomib treatment (see section 4.8).

At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, ixazomib should be withdrawn immediately and an alternative treatment considered (as appropriate).

If the patient has developed a serious reaction such as SJS or TEN with the use of ixazomib, treatment with ixazomib must not be restarted in this patient at any time.

Thrombotic microangiopathy

Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP), have been reported in patients who received ixazomib. Some of these events have been fatal. Signs and symptoms of TMA should be monitored for. If the diagnosis is suspected, stop ixazomib and evaluate patients for possible TMA. If the diagnosis of TMA is excluded, ixazomib can be restarted. The safety of reinitiating ixazomib therapy in patients previously experiencing TMA is not known.

Hepatotoxicity

Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have been uncommonly reported with ixazomib (see section 4.8). Hepatic enzymes should be monitored regularly and the dose should be adjusted for Grade 3 or 4 symptoms (see section 4.2).

Pregnancy

Women should avoid becoming pregnant while being treated with ixazomib. If ixazomib is used during pregnancy or if the patient becomes pregnant while taking ixazomib, the patient should be apprised of the potential hazard to the foetus.

Women of childbearing potential must use highly effective contraception while taking ixazomib and for 90 days after stopping treatment (see sections 4.5 and 4.6). Women using hormonal contraceptives should additionally use a barrier method of contraception.

Posterior reversible encephalopathy syndrome

Posterior reversible encephalopathy syndrome (PRES) has occurred in patients receiving ixazomib. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, altered consciousness, and visual disturbances. Brain imaging, preferably Magnetic Resonance Imaging, is used to confirm the diagnosis. In patients developing PRES, discontinue ixazomib.

Strong CYP3A inducers

Strong inducers may reduce the efficacy of ixazomib, therefore the concomitant use of strong CYP3A inducers such as carbamazepine, phenytoin, rifampicin and St. John's Wort (*Hypericum perforatum*), should be avoided (see sections 4.5 and 5.2). Closely monitor patients for disease control if co-administration with a strong CYP3A inducer cannot be avoided.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacokinetic interactions

CYP inhibitors

Co-administration of ixazomib with clarithromycin, a strong CYP3A inhibitor, did not result in a clinically meaningful change in the systemic exposure of ixazomib. Ixazomib C_{max} was decreased by 4% and AUC was increased by 11%. Therefore, no dose modification is required for ixazomib with co-administration of strong CYP3A inhibitors.

Co-administration of ixazomib with strong CYP1A2 inhibitors did not result in a clinically meaningful change in the systemic exposure of ixazomib based on the results of a population pharmacokinetic (PK) analysis. Therefore, no dose modification is required for ixazomib with co-administration of strong CYP1A2 inhibitors.

CYP inducers

Co-administration of ixazomib with rifampicin decreased ixazomib C_{max} by 54% and AUC by 74%. Therefore, co-administration of strong CYP3A inducers with ixazomib is not recommended (see section 4.4).

Effect of ixazomib on other medicinal products

Ixazomib is not a reversible or a time-dependent inhibitor of CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5. Ixazomib did not induce CYP1A2, CYP2B6, and CYP3A4/5 activity or corresponding immunoreactive protein levels. Ixazomib is not expected to produce drug-drug interactions via CYP inhibition or induction.

Transporter-based interactions

Ixazomib is a low affinity substrate of P-gp. Ixazomib is not a substrate of BCRP, MRP2 or hepatic OATPs. Ixazomib is not an inhibitor of P-gp, BCRP, MRP2, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, or MATE2-K. Ixazomib is not expected to cause transporter-mediated drug-drug interactions.

Oral contraceptives

When ixazomib is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered. Women using hormonal contraceptives should additionally use a barrier method of contraception.

4.6 Fertility, pregnancy and lactation

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional information on fertility, pregnancy and lactation.

Women of childbearing potential/Contraception in males and females

Male and female patients who are able to have children must use effective contraceptive measures during and for 90 days following treatment. Ixazomib is not recommended in women of childbearing potential not using contraception.

When ixazomib is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy

of oral contraceptives needs to be considered. Therefore, women using oral hormonal contraceptives should additionally use a barrier method of contraception.

Pregnancy

Ixazomib is not recommended during pregnancy as it can cause foetal harm when administered to a pregnant woman. Therefore, women should avoid becoming pregnant while being treated with ixazomib.

There are no data for the use of ixazomib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).

Ixazomib is given in combination with lenalidomide. Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. If lenalidomide is taken during pregnancy, a teratogenic effect in humans is expected. The conditions of the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential. Please refer to the current lenalidomide SmPC.

Breast-feeding

It is unknown whether ixazomib or its metabolites are excreted in human milk. No animal data are available. A risk to newborns/infants cannot be excluded and therefore breast-feeding should be discontinued.

Ixazomib will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.

Fertility

Fertility studies have not been conducted with ixazomib (see section 5.3).

4.7 Effects on ability to drive and use machines

Ixazomib has minor influence on the ability to drive or use machines. Fatigue and dizziness have been observed in clinical trials. Patients should be advised not to drive or operate machines if they experience any of these symptoms.

4.8 Undesirable effects

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional undesirable effects.

Summary of the safety profile

The safety profile of NINLARO is based on available clinical trial data and post-marketing experience to date. Frequencies of adverse reactions described below and in Table 3 have been determined based on data generated from clinical studies.

Unless otherwise noted, the data presented below is the pooled safety data from the pivotal, Phase 3, global C16010 study (n = 720) and the double-blind, placebo-controlled C16010 China Continuation Study (n = 115). The most frequently reported adverse reactions ($\geq 20\%$) across 418 patients treated within the ixazomib regimen and 417 patients within the placebo regimen were diarrhoea (47% vs. 38%), thrombocytopenia (41% vs. 24%), neutropenia (37% vs. 36%), constipation (31% vs. 24%), upper respiratory tract infection (28% vs. 24%), peripheral neuropathy (28% vs. 22%), nausea (28% vs. 20%), back pain (25% vs. 21%), rash (25% vs. 15%), peripheral oedema (24% vs. 19%), vomiting

(23% vs. 12%) and bronchitis (20% vs. 15%). Serious adverse reactions reported in $\geq 2\%$ of patients included diarrhoea (3%), thrombocytopenia (2%) and bronchitis (2%).

Tabulated list of adverse reactions

The following convention is used for the classification of the frequency of an adverse drug reaction (ADR): very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1\ 000$ to $< 1/100$); rare ($\geq 1/10\ 000$ to $< 1/1\ 000$); very rare ($< 1/10\ 000$); not known (cannot be estimated from the available data). Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 3: Adverse reactions in patients treated with ixazomib in combination with lenalidomide and dexamethasone (all grades, grade 3 and grade 4)

| System organ class / Adverse reaction | Adverse reactions (all grades) | Grade 3 adverse reactions | Grade 4 adverse reactions |
|---|--------------------------------|---------------------------|---------------------------|
| Infections and infestations | | | |
| Upper respiratory tract infection | Very common | Common | |
| Bronchitis | Very common | Common | |
| Herpes zoster | Common | Common | |
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia* | Very common | Very common | Common |
| Neutropenia* | Very common | Very common | Common |
| Thrombotic microangiopathy | Rare | | Rare |
| Thrombotic thrombocytopenic purpura [†] | Rare | Rare | Rare |
| Immune system disorders | | | |
| Anaphylactic reaction [†] | Rare | Very rare | Very rare |
| Angioedema [†] | Rare | Rare | |
| Metabolism and nutrition disorders | | | |
| Tumour lysis syndrome [†] | Rare | Rare | Rare |
| Nervous system disorders | | | |
| Peripheral neuropathies* | Very common | Common | |
| Posterior reversible encephalopathy disorders* [†] | Rare | Rare | Rare |
| Transverse myelitis [†] | Rare | Rare | |
| Gastrointestinal disorders | | | |
| Diarrhoea | Very common | Common | |
| Constipation | Very common | Uncommon | |
| Nausea | Very common | Common | |
| Vomiting | Very common | Uncommon | |
| Skin and subcutaneous tissue disorders | | | |
| Rash* | Very common | Common | |
| Stevens-Johnson syndrome [†] | Rare | Rare | |
| Acute febrile neutrophilic dermatosis | Rare | Rare | |
| Toxic epidermal necrolysis [†] | Rare | | Rare |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | Very common | Uncommon | |
| Arthralgia | Very common | Common | |

| System organ class / Adverse reaction | Adverse reactions (all grades) | Grade 3 adverse reactions | Grade 4 adverse reactions |
|---|--------------------------------|---------------------------|---------------------------|
| General disorders and administration site conditions | | | |
| Oedema peripheral | Very common | Common | |
| Pyrexia | Very common | Uncommon | |

*Represents a pooling of preferred terms

†Reported outside of the Phase 3 studies

Description of selected adverse reactions

Discontinuations

For each adverse reaction, one or more of the three medicinal products was discontinued in $\leq 3\%$ of patients in the ixazomib regimen.

Thrombocytopenia

Two percent of patients in both the ixazomib regimen and the placebo regimen had a platelet count $\leq 10\,000/\text{mm}^3$ during treatment. Less than 1% of patients in both regimens had a platelet count $\leq 5\,000/\text{mm}^3$ during treatment. Thrombocytopenia resulted in discontinuation of one or more of the three medicinal products in 2% of patients in the ixazomib regimen and 3% of patients in the placebo regimen. Thrombocytopenia did not result in an increase in haemorrhagic events or platelet transfusions.

Gastrointestinal toxicities

Diarrhoea resulted in discontinuation of one or more of the three medicinal products in 2% of patients in the ixazomib regimen and 1% of patients in the placebo regimen.

Rash

Rash occurred in 25% of patients in the ixazomib regimen compared to 15% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Grade 3 rash was reported in 3% of patients in the ixazomib regimen compared to 2% of patients in the placebo regimen. Rash resulted in discontinuation of one or more of the three medicinal products in $< 1\%$ of patients in both regimens.

Peripheral neuropathy

Peripheral neuropathy occurred in 28% of patients in the ixazomib regimen compared to 22% of patients in the placebo regimen. Grade 3 adverse reactions of peripheral neuropathy were reported in 2% of patients in the ixazomib regimen compared to 1% in the placebo regimen. The most commonly reported reaction was peripheral sensory neuropathy (21% and 15% in the ixazomib and placebo regimen, respectively). Peripheral motor neuropathy was not commonly reported in either regimen ($< 1\%$). Peripheral neuropathy resulted in discontinuation of one or more of the three medicinal products in 3% of patients in the ixazomib regimen compared to $< 1\%$ of patients in the placebo regimen.

Eye disorders

Eye disorders were reported with many different preferred terms but in aggregate, the frequency was 34% in patients in the ixazomib regimen and 28% of patients in the placebo regimen. The most common adverse reactions were blurred vision (6% in the ixazomib regimen and 5% in the placebo regimen), dry eye (6% in the ixazomib regimen and 1% in the placebo regimen), conjunctivitis (8% in the ixazomib regimen and 2% in the placebo regimen) and cataract (13% in the ixazomib regimen and 17% in the placebo regimen). Grade 3 adverse reactions were reported in 6% of patients in the ixazomib regimen and 8% of patients in the placebo regimen.

Other adverse reactions

In the pooled dataset from the pivotal, Phase 3, global C16010 study (n = 720) and the double-blind, placebo-controlled, C16010 China Continuation Study (n = 115), the following adverse reactions occurred with a similar rate between the ixazomib and placebo regimens: fatigue (28% vs. 26%), decreased appetite (13% vs. 11%), hypotension (5% vs. 4%), heart failure[†] (5% each), arrhythmia[†] (17% vs. 16%), and liver impairment including enzyme changes[†] (11% vs. 9%).

The frequency of severe (Grade 3-4) events of hypokalaemia was higher in the ixazomib regimen (7%) than the placebo regimen (2%).

Fungal and viral pneumonia resulting in fatal outcome were rarely reported in patients given the ixazomib, lenalidomide and dexamethasone combination.

[†] Standardised MedDRA Queries (SMQs)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

4.9 Overdose

Overdose has been reported in patients taking NINLARO. Symptoms of overdose are generally consistent with the known risks of NINLARO (see section 4.8). Overdose of 12 mg (taken at one time) has resulted in serious adverse events, such as severe nausea, aspiration pneumonia, multiple organ failure and death.

There is no known specific antidote for ixazomib overdose. In the event of an overdose, monitor the patient closely for adverse reactions (see section 4.8) and provide appropriate supportive care. Ixazomib is not dialyzable (see section 5.2).

Overdoses were most common in patients starting treatment with NINLARO. The importance of carefully following all dosage instructions should be discussed with patients starting treatment. Instruct patients to take the recommended dosage as directed because overdose has led to deaths.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XG03.

Mechanism of action

Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses under physiological conditions to its biologically active form, ixazomib.

Ixazomib is an oral, highly selective and reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.

Ixazomib induced apoptosis of several tumour cell types *in vitro*. Ixazomib demonstrated *in vitro* cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and

lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. *In vivo*, ixazomib demonstrated antitumour activity in various tumour xenograft models, including models of multiple myeloma. *In vitro*, ixazomib affected cell types found in the bone marrow microenvironment including vascular endothelial cells, osteoclasts and osteoblasts.

Cardiac electrophysiology

Ixazomib did not prolong the QTc interval at clinically relevant exposures based on the results of a pharmacokinetic-pharmacodynamic analysis of data from 245 patients. At the 4 mg dose, mean change from baseline in QTcF was estimated to be 0.07 msec (90% CI; -0.22, 0.36) from the model based analysis. There was no discernible relationship between ixazomib concentration and the RR interval suggesting no clinically meaningful effect of ixazomib on heart rate.

Clinical efficacy and safety

The efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone was evaluated in an international randomised, double-blind, placebo-controlled, multicenter Phase 3 superiority study (C16010) in patients with relapsed and/or refractory multiple myeloma who had received at least one prior therapy. A total of 722 patients (intent-to-treat [ITT] population) were randomised in a 1:1 ratio to receive either the combination of ixazomib, lenalidomide, and dexamethasone (N = 360; ixazomib regimen) or placebo, lenalidomide and dexamethasone (N = 362; placebo regimen) until disease progression or unacceptable toxicity. Patients enrolled in the trial had multiple myeloma that was refractory, including primary refractory, had relapsed after prior therapy, or had relapsed and was refractory to any prior therapy. Patients that changed therapies prior to disease progression were eligible for enrolment, as well as those with controlled cardiovascular conditions. The Phase 3 study excluded patients who were refractory to lenalidomide or proteasome inhibitors and patients who received more than three prior therapies. For the purposes of this study, refractory disease was defined as disease progression on treatment or progression within 60 days after the last dose of lenalidomide or a proteasome inhibitor. As data are limited in these patients, a careful risk-benefit assessment is recommended before initiating the ixazomib regimen.

Thromboprophylaxis was recommended for all patients in both treatment groups according to the lenalidomide SmPC. Concomitant medicinal products, such as antiemetic, antiviral, and antihistamine medicinal products were given to patients at the physician's discretion as prophylaxis and/or management of symptoms.

Patients received ixazomib 4 mg or placebo on Days 1, 8, and 15 plus lenalidomide (25 mg) on Days 1 through 21 and dexamethasone (40 mg) on Days 1, 8, 15, and 22 of a 28-day cycle. Patients with renal impairment received a starting dose of lenalidomide according to its SmPC. Treatment continued until disease progression or unacceptable toxicities.

The baseline demographics and disease characteristics were balanced and comparable between the study regimens. The median age was 66 years, range 38-91 years; 58% of patients were older than 65 years. Fifty seven percent of patients were male. Eighty five percent of the population was White, 9% Asian and 2% Black. Ninety three percent of patients had an ECOG performance status of 0-1 and 12% had baseline ISS stage III disease (N = 90). Twenty five percent of patients had a creatinine clearance of < 60 mL/min. Twenty three percent of patients had light chain disease and 12% of patients had measurable disease by free light chain assay only. Nineteen percent had high-risk cytogenetic abnormalities (del[17], t[4;14], t[14;16]) (N = 137), 10% had del(17) (N = 69) and 34% had 1q amplification (1q21) (N = 247). Patients received one to three prior therapies (median of 1) including prior treatment with bortezomib (69%), carfilzomib (< 1%), thalidomide (45%), lenalidomide (12%), melphalan (81%). Fifty seven percent of patients had undergone prior stem cell transplantation. Seventy seven percent of patients relapsed after prior therapies and 11% were refractory to prior therapies. Primary refractory, defined as best response of stable disease or disease progression on all prior therapies, was documented in 6% of patients.

The primary endpoint was progression-free survival (PFS) according to the 2011 International Myeloma Working Group (IMWG) Consensus Uniform Response Criteria as assessed by a blinded independent review committee (IRC) based on central laboratory results. Response was assessed every 4 weeks until disease progression. At the primary analysis (median follow up of 14.7 months and a median of 13 cycles), PFS was statistically significantly different between the treatment arms. PFS results are summarised in Table 4 and Figure 1. The improvement in PFS in the ixazomib regimen was supported by improvements in overall response rate.

Table 4: Progression free survival and response Results in multiple myeloma patients treated with ixazomib or placebo in combination with lenalidomide and dexamethasone (intent-to-treat population, primary analysis)

| | Ixazomib + Lenalidomide and Dexamethasone (N = 360) | Placebo + Lenalidomide and Dexamethasone (N = 362) |
|---|---|--|
| Progression-Free Survival | | |
| Events, n (%) | 129 (36) | 157 (43) |
| Median (months) | 20.6 | 14.7 |
| p-value* | 0.012 | |
| Hazard Ratio [†] (95% CI) | 0.74 (0.59, 0.94) | |
| Overall Response Rate[‡], n (%) | 282 (78.3) | 259 (71.5) |
| Response Category, n (%) | | |
| Complete Response | 42 (11.7) | 24 (6.6) |
| Very Good Partial Response | 131 (36.4) | 117 (32.3) |
| Partial Response | 109 (30.3) | 118 (32.6) |
| Time to Response, months | | |
| Median | 1.1 | 1.9 |
| Duration of Response[§], months | | |
| Median | 20.5 | 15.0 |


*P-value is based on the stratified log-rank test.

[†]Hazard ratio is based on a stratified Cox's proportional hazard regression model. A hazard ratio less than 1 indicates an advantage for the ixazomib regimen.

[‡]ORR = CR+VGPR+PR

[§]Based on responders in the response-evaluable population

Figure 1: Kaplan-Meier plot of progression-free survival in the intent-to-treat population (primary analysis)




A second, non-inferential, PFS analysis was conducted with a median follow up of 23 months. At this analysis, estimated median PFS was 20 months in the ixazomib regimen and 15.9 months in the placebo regimen (HR = 0.82 [95% CI (0.67, 1.0)]) in the ITT population. For patients with one prior therapy, the median PFS was 18.7 months in the ixazomib regimen and 17.6 months in the placebo regimen (HR = 0.99). For patients with 2 or 3 prior therapies, PFS was 22.0 months in the ixazomib regimen and 13.0 months in the placebo regimen (HR = 0.62).

At the final analysis for OS at a median duration of follow up of approximately 85 months, median OS in the ITT population was 53.6 months for patients in the ixazomib regimen and 51.6 months for patients in the placebo regimen (HR = 0.94 [95% CI: 0.78, 1.13; p = 0.495]). For patients with one prior therapy, the median OS was 54.3 months in the ixazomib regimen and 58.3 months in the placebo regimen (HR = 1.02 [95% CI: 0.80, 1.29]). For patients with 2 or 3 prior therapies, the median OS was 53.0 months in the ixazomib regimen and 43.0 months in the placebo regimen (HR = 0.85 [95% CI: 0.64, 1.11]).

A randomised, double-blind, placebo-controlled Phase 3 study was conducted in China (N = 115) with a similar study design and eligibility criteria. Many of the patients enrolled in the study had advanced disease with Durie-Salmon Stage III (69%) at initial diagnosis and a treatment history of receiving at least 2 prior therapies (60%) and being thalidomide refractory (63%). At the primary analysis (median follow up of 8 months and a median of 6 cycles), the median PFS was 6.7 months in the ixazomib regimen compared to 4 months in the placebo regimen (p-value = 0.035, HR = 0.60). At the final analysis for OS at a median follow up of 19.8 months, OS was improved for patients treated in the ixazomib regimen compared with placebo [p-value = 0.0014, HR = 0.42, 95% CI: 0.242, 0.726).

As multiple myeloma is a heterogeneous disease, benefit may vary across subgroups in the Phase 3 study (C16010) (see Figure 2).

Figure 2: Forest plot of progression-free survival in subgroups



In the Phase 3 study (C16010), 10 patients (5 in each treatment regimen) had severe renal impairment at baseline. Of the 5 patients in the ixazomib regimen, one patient had a confirmed partial response and 3 confirmed stable disease (however 2 were unconfirmed partial response and 1 was an unconfirmed very good partial response). Of the 5 patients in the placebo regimen, 2 had a confirmed very good partial response.

Quality of life as assessed by global health scores (EORTC QLQ-C30 and MY-20) was maintained during treatment and was similar in both treatment regimens in the Phase 3 study (C16010).

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with ixazomib in all subsets of the paediatric population in multiple myeloma (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

After oral administration, peak plasma concentrations of ixazomib were achieved at approximately one hour after dosing. The mean absolute oral bioavailability is 58%. Ixazomib AUC increases in a dose proportional manner over a dose range of 0.2-10.6 mg.

Administration with a high-fat meal decreased ixazomib AUC by 28% compared with administration after an overnight fast (see section 4.2).

Distribution

Ixazomib is 99% bound to plasma proteins and distributes into red blood cells with a blood-to-plasma AUC ratio of 10. The steady-state volume of distribution is 543 L.

Biotransformation

After oral administration of a radiolabeled dose, 70% of total drug-related material in plasma was accounted for by ixazomib. Metabolism by multiple CYP enzymes and non-CYP proteins is expected to be the major clearance mechanism for ixazomib. At clinically relevant ixazomib concentrations, *in vitro* studies using human cDNA-expressed cytochrome P450 isozymes indicate that no specific CYP isozyme predominantly contributes to ixazomib metabolism and non-CYP proteins contribute to overall metabolism. At concentrations exceeding those observed clinically, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42.3%), 1A2 (26.1%), 2B6 (16.0%), 2C8 (6.0%), 2D6 (4.8%), 2C19 (4.8%) and 2C9 (< 1%).

Elimination

Ixazomib exhibits a multi-exponential disposition profile. Based on a population PK analysis, systemic clearance (CL) was approximately 1.86 L/hr with inter-individual variability of 44%. The terminal half-life ($t_{1/2}$) of ixazomib was 9.5 days. Approximately 2-fold accumulation in AUC was observed with weekly oral dosing on Day 15.

Excretion

After administration of a single oral dose of ^{14}C -ixazomib to 5 patients with advanced cancer, 62% of the administered radioactivity was excreted in urine and 22% in the faeces. Unchanged ixazomib accounted for < 3.5% of the administered dose recovered in urine.

Special populations

Hepatic impairment

The PK of ixazomib is similar in patients with normal hepatic function and in patients with mild hepatic impairment (total bilirubin \leq ULN and AST $>$ ULN or total bilirubin $>$ 1-1.5 x ULN and any AST) based on the results of a population PK analysis.

The PK of ixazomib was characterized in patients with normal hepatic function at 4 mg (N = 12), moderate hepatic impairment at 2.3 mg (total bilirubin $>$ 1.5-3 x ULN, N = 13) or severe hepatic impairment at 1.5 mg (total bilirubin $>$ 3 x ULN, N = 18). Unbound dose-normalized AUC was 27% higher in patients with moderate or severe hepatic impairment as compared to patients with normal hepatic function (see section 4.2).

Renal impairment

The PK of ixazomib is similar in patients with normal renal function and in patients with mild or moderate renal impairment (creatinine clearance \geq 30 mL/min) based on the results of a population PK analysis.

The PK of ixazomib was characterized at a dose of 3 mg in patients with normal renal function (creatinine clearance \geq 90 mL/min, N = 18), severe renal impairment (creatinine clearance $<$ 30 mL/min, N = 14), or ESRD requiring dialysis (N = 6). Unbound AUC was 38% higher in patients with severe renal impairment or ESRD requiring dialysis as compared to patients with normal renal

function. Pre- and post-dialyzer concentrations of ixazomib measured during the haemodialysis session were similar, suggesting that ixazomib is not dialyzable (see section 4.2).

Age, gender, race

There was no clinically meaningful effect of age (23-91 years), sex, body surface area (1.2-2.7 m²), or race on the clearance of ixazomib based on the results of a population PK analysis. The mean AUC was 35% higher in Asian patients; however, there was overlap in the AUC of ixazomib across White and Asian patients.

5.3 Preclinical safety data

Mutagenicity

Ixazomib was not mutagenic in a bacterial reverse mutation assay (Ames assay) or clastogenic in a bone marrow micronucleus assay in mice. Ixazomib was positive in an *in vitro* clastogenicity test in human peripheral blood lymphocytes. However, ixazomib was negative in an *in vivo* comet assay in mice, in which percent tail DNA was assessed in the stomach and liver. Therefore, the weight of evidence indicates that ixazomib is not considered to present a genotoxic risk.

Reproductive and embryo-foetal development

Ixazomib caused embryo-foetal toxicity in pregnant rats and rabbits only at maternally toxic doses and at exposures that were slightly higher than those observed in patients receiving the recommended dose. Studies of fertility and early embryonic development and pre- and post-natal toxicology were not conducted with ixazomib, but evaluation of reproductive tissues was conducted in the general toxicity studies. There were no effects due to ixazomib treatment on male or female reproductive organs in studies up to 6-months duration in rats and up to 9-months duration in dogs.

Animal toxicology and/or pharmacology

In multi-cycle repeated-dose toxicity studies conducted in rats and dogs, the principal target organs included the gastrointestinal tract, lymphoid tissues, and the nervous system. In the 9-month study (10 cycles) in dogs orally administered with a dosing schedule mimicking the clinical regimen (28-day cycle), microscopic neuronal effects were generally minimal in nature and only observed at 0.2 mg/kg (4 mg/m²). The majority of target organ findings demonstrated partial to full recovery following discontinuation of treatment, with the exception of neuronal findings in the lumbar dorsal root ganglion and dorsal column.

Following oral administration, a tissue distribution study in rats revealed that the brain and spinal cord were amongst the tissues with the lowest levels, suggesting that the penetration of ixazomib through the blood-brain barrier appears to be limited. However, the relevance to humans is unknown.

Non-clinical safety pharmacology studies both *in vitro* (on hERG channels) and *in vivo* (in telemetered dogs following single oral administration) demonstrated no effects of ixazomib on cardiovascular or respiratory functions at AUC more than 8-fold higher than the clinical value.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

NINLARO 2.3 mg hard capsules

Capsule contents

Microcrystalline cellulose
Magnesium stearate
Talc

Capsule shell

Gelatin
Titanium dioxide (E171)
Red iron oxide (E172)

Printing ink

Shellac
Propylene glycol
Potassium hydroxide
Black iron oxide (E172)

NINLARO 3 mg hard capsules

Capsule contents

Microcrystalline cellulose
Magnesium stearate
Talc

Capsule shell

Gelatin
Titanium dioxide (E171)
Black iron oxide (E172)

Printing ink

Shellac
Propylene glycol
Potassium hydroxide
Black iron oxide (E172)

NINLARO 4 mg hard capsules

Capsule contents

Microcrystalline cellulose
Magnesium stearate
Talc

Capsule shell

Gelatin
Titanium dioxide (E171)
Yellow iron oxide (E172)
Red iron oxide (E172)

Printing ink

Shellac
Propylene glycol
Potassium hydroxide

Black iron oxide (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 30 °C. Do not freeze.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC-Aluminium /Aluminium blister strip containing three capsules, sealed inside a wallet pack. One wallet pack is packaged in one carton.

6.6 Special precautions for disposal and other handling

Ixazomib is cytotoxic. The capsule should not be removed until just prior to dosing. The capsules should not be opened or crushed. Direct contact with the capsule contents should be avoided. In case of capsule breakage, avoid raising dust during clean-up. If contact occurs, wash thoroughly with soap and water.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark
medinfoEMEA@takeda.com

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1094/001
EU/1/16/1094/002
EU/1/16/1094/003

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 November 2016
Date of latest renewal: 01 September 2023

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

ANNEX II

- A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Takeda Ireland Limited
Grange Castle Business Park
Nangor Road
Dublin 22
D22 XR57
Ireland

Takeda GmbH
Takeda (Werk Singen)
Robert Bosch Strasse 8
78224 Singen
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON CONTAINING WALLET UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 2.3 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE

Each hard capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate).

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

1 pack of 3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C. Do not freeze.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

NINLARO 2.3 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING

WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 2.3 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.

Do not crush, open or chew the capsules. Take each NINLARO capsule whole with water at the same time each week, at least one hour before or no sooner than two hours after any food.

The capsule should not be removed until just prior to dosing.

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

To access capsule, gently press on blue tab.

16. INFORMATION IN BRAILLE

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER FOR WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 2.3 mg
ixazomib

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Takeda

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON CONTAINING WALLET UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 3 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE

Each hard capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate).

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

1 pack of 3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C. Do not freeze.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

NINLARO 3 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING

WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 3 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.

Do not crush, open or chew the capsules. Take each NINLARO capsule whole with water at the same time each week, at least one hour before or no sooner than two hours after any food.

The capsule should not be removed until just prior to dosing.

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

To access capsule, gently press on blue tab.

16. INFORMATION IN BRAILLE

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER FOR WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 3 mg
ixazomib

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Takeda

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON CONTAINING WALLET UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 4 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE

Each hard capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib citrate).

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

1 pack of 3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30 °C. Do not freeze.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

NINLARO 4 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING

WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 4 mg hard capsules
ixazomib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Hard capsule

3 hard capsules

5. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.

Do not crush, open or chew the capsules. Take each NINLARO capsule whole with water at the same time each week, at least one hour before or no sooner than two hours after any food.

The capsule should not be removed until just prior to dosing.

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

7. OTHER SPECIAL WARNING, IF NECESSARY

Cytotoxic

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Takeda Pharma A/S

12. MARKETING AUTHORISATION NUMBER

EU/1/16/1094/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

To access capsule, gently press on blue tab.

16. INFORMATION IN BRAILLE

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER FOR WALLET

1. NAME OF THE MEDICINAL PRODUCT

NINLARO 4 mg
ixazomib

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Takeda

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

NINLARO 2.3 mg hard capsules

NINLARO 3 mg hard capsules

NINLARO 4 mg hard capsules

ixazomib

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What NINLARO is and what it is used for
2. What you need to know before you take NINLARO
3. How to take NINLARO
4. Possible side effects
5. How to store NINLARO
6. Contents of the pack and other information

1. What NINLARO is and what it is used for

What NINLARO is

NINLARO is a cancer medicine that contains ixazomib, a ‘proteasome inhibitor’.

NINLARO is used to treat a cancer of the bone marrow called multiple myeloma. Its active substance ixazomib works by blocking the action of proteasomes. These are structures inside the cell that digest proteins and are important for cell survival. Because myeloma cells produce a lot of proteins, blocking the action of proteasomes can kill the cancerous cells.

What NINLARO is used for

NINLARO is used to treat adults with multiple myeloma. NINLARO will be given to you together with lenalidomide and dexamethasone, which are other medicines used to treat multiple myeloma.

What multiple myeloma is

Multiple myeloma is a cancer of the blood which affects a type of cell, called the plasma cell. A plasma cell is a blood cell that normally produces proteins to fight infections. People with multiple myeloma have cancerous plasma cells, also called myeloma cells, which can damage the bones. Protein produced by myeloma cells can damage the kidneys. Treatment for multiple myeloma involves killing myeloma cells and reducing the symptoms of the disease.

2. What you need to know before you take NINLARO

Do not take NINLARO

- if you are allergic to ixazomib or to any of the other ingredients of this medicine (listed in section 6).

If you are uncertain whether the condition above applies to you, talk to your doctor, pharmacist or nurse before taking NINLARO.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking or during treatment with NINLARO if:

- you have a history of bleeding
- you have persistent nausea, vomiting or diarrhoea
- you have a history of nerve problems, to include tingling and numbness
- you have a history of swelling
- you have a persistent rash or a severe skin rash with skin peeling and mouth sores (Stevens Johnson syndrome or toxic epidermal necrolysis, see section 4)
- you have or have had liver or kidney problems as your dose may have to be adjusted
- you have or have had damage to the smallest blood vessels known as thrombotic microangiopathy or thrombotic thrombocytopenic purpura. Tell your doctor if you develop fatigue, fever, bruising, bleeding, decreased urination, swelling, confusion, vision loss, and seizures.

Your doctor will examine you and you will be monitored closely during treatment. Before starting NINLARO and during treatment, you will have blood tests to check that you have enough blood cells.

Children and adolescents

NINLARO is not recommended for use in children and adolescents aged under 18 years.

Other medicines and NINLARO

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This includes any medicines obtained without a prescription, such as vitamins or herbal remedies. This is because other medicines can affect the way NINLARO works. In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines: carbamazepine, phenytoin, rifampicin and St. John's wort (*Hypericum perforatum*). These medicines should be avoided as they may reduce the effectiveness of NINLARO.

Pregnancy and breast-feeding

NINLARO is not recommended during pregnancy as it may harm your unborn baby. Breast-feeding should be stopped when taking NINLARO.

Avoid becoming pregnant or breast-feeding while being treated with NINLARO. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

If you are a woman of childbearing potential or a man who can father a child, you must use effective contraception during and for 90 days after treatment. Women using hormonal contraceptives should additionally use a barrier method of contraception. Tell doctor right away if you or your partner becomes pregnant while receiving NINLARO.

As NINLARO is given in combination with lenalidomide, you should adhere to the pregnancy prevention programme of lenalidomide because lenalidomide can be harmful to the unborn child.

See the package leaflets for lenalidomide and dexamethasone for additional information on pregnancy and breast-feeding

Driving and using machines

NINLARO may affect your ability to drive or use machines. You may feel tired and dizzy while taking NINLARO. Do not drive or operate machines if you have these side effects.

3. How to take NINLARO

NINLARO must be prescribed to you by a doctor with experience of treating multiple myeloma. Always take this medicine exactly as your doctor or pharmacist has told you.

NINLARO is used with lenalidomide (a medicine which affects how your immune system works) and dexamethasone (an anti-inflammatory medicine).

NINLARO, lenalidomide and dexamethasone are taken in 4-week treatment cycles. NINLARO is taken once a week (on the same day of the week) for the first 3 weeks of this cycle. The recommended dose is one 4 mg capsule taken by mouth.

The recommended dose of lenalidomide is 25 mg taken every day for the first 3 weeks of the cycle. The recommended dose of dexamethasone is 40 mg taken once a week on the same day for all 4 weeks of the cycle.

| Dosing schedule: NINLARO taken with lenalidomide and dexamethasone | | | | | | | | |
|---|---------------|-------------|---------------|--------------|---------------|---------------|---------------|---------------|
| ✓ Take medicine | | | | | | | | |
| 28-day cycle (a 4-week cycle) | | | | | | | | |
| | Week 1 | | Week 2 | | Week 3 | | Week 4 | |
| | Day 1 | Days 2 to 7 | Day 8 | Days 9 to 14 | Day 15 | Days 16 to 21 | Day 22 | Days 23 to 28 |
| NINLARO | ✓ | | ✓ | | ✓ | | | |
| Lenalidomide | ✓ | ✓ Daily | ✓ | ✓ Daily | ✓ | ✓ Daily | | |
| Dexamethasone | ✓ | | ✓ | | ✓ | | ✓ | |

You should read the Package Leaflets of these other medicines for further information on their use and effects.

If you have liver or kidney problems, your doctor may prescribe NINLARO capsules containing 3 mg. If you have side effects, your doctor may prescribe NINLARO capsules containing 3 mg or 2.3 mg. The doctor may also adjust the doses of the other medicines.

How and when to take NINLARO

- Take NINLARO at least one hour before or at least two hours after food.
- Swallow the capsule whole with water. Do not crush, chew or open the capsule.
- Do not let the contents of the capsule come into contact with your skin. If the powder accidentally comes into contact with your skin, wash it off thoroughly with soap and water. If the capsule breaks, clean up the powder, taking care that it does not cause dust in the air.

If you take more NINLARO than you should

Accidental overdose can cause serious side effects. If you take more NINLARO than you should, talk to a doctor immediately or go to a hospital straight away. Take the medicine pack with you.

Duration of the treatment with NINLARO

You should continue treatment until your doctor tells you to stop.

If you forget to take NINLARO

If a dose is missed or delayed, you should take the dose as long as the next scheduled dose is more than 3 days or 72 hours away. Do not take a missed dose if it is within 3 days or 72 hours of your next scheduled dose.

If you vomit after taking a dose, do not take an extra dose. Take the next dose, as normal, when it is due.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop using ixazomib and seek medical attention immediately if you notice any of the following symptoms:

- reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis, which may affect up to 1 in 1 000 people).

Tell your doctor or pharmacist straight away if you notice any of these following very common serious side effects which may affect more than 1 in 10 people:

- low platelet counts (thrombocytopenia) which may increase the risk of nose bleeds and you may easily bruise
- nausea, vomiting and diarrhoea
- numbness, tingling or burning of the hands or feet (peripheral neuropathy)
- swelling of the legs or feet (peripheral oedema)
- skin rash that may be itchy and in a few areas or all over the body
- cough, chest soreness or pain, or nasal congestion (bronchitis)

Additionally, tell a doctor immediately if you notice any of these following rare side effects which may affect up to 1 in 1 000 people:

- severe skin rashes such as red to purple bumps (Sweet's syndrome)
- muscle weakness, loss of feelings of the toes and feet or loss of leg movement (transverse myelitis)
- changes in vision, changes in mental status, or seizures (posterior reversible encephalopathy syndrome)
- rapid death of cancer cells that may cause dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances (tumour lysis syndrome)
- rare blood condition resulting from blood clots that may cause fatigue, fever, bruising, bleeding e.g. nose bleeds, decreased urination, swelling, confusion, vision loss, and seizures (thrombotic microangiopathy, thrombotic thrombocytopenic purpura)
- swelling of the face, lips, tongue or throat, trouble breathing or swallowing, wheezing, chest tightness or dizziness, skin itching and hives (angioedema or anaphylactic reaction)

Other possible side effects

Tell your doctor or pharmacist if any of the side effects below become severe.

Very common: may affect more than 1 in 10 people

- constipation
- back pain
- cold-like symptoms (upper respiratory tract infection)
- feeling tired or weak (fatigue)
- fever (pyrexia)
- joint pain (arthralgia)
- lowered white blood cells called neutrophils (neutropenia) that may increase the risk of infection
- not feeling like eating (decreased appetite)
- irregular heart rate (arrhythmia)
- vision conditions including blurred vision, dry eye and pink eye (conjunctivitis)

Common: may affect up to 1 in 10 people

- reactivation of the chicken pox virus (shingles) that can cause a skin rash and pain (herpes zoster)
- lowered blood pressure (hypotension)
- shortness of breath or persistent coughing or wheezing (heart failure)
- yellow discoloration of eyes and skin (jaundice which could be a symptom of liver impairment)
- low levels of potassium in the blood (hypokalaemia)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system](#) listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store NINLARO

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister, wallet and carton after EXP. The expiry date refers to the last day of that month.

Do not store above 30 °C. Do not freeze.

Store in the original package in order to protect from moisture.

Do not remove the capsule until you need to take a dose.

Do not use this medicine if you notice any damage or signs of tampering to medicine packaging.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What NINLARO contains

NINLARO 2.3 mg hard capsule:

- The active substance is ixazomib. Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate).
- The other ingredients are:
 - In the capsule: microcrystalline cellulose, magnesium stearate and talc.
 - The capsule shell contains: gelatin, titanium dioxide (E171) and red iron oxide (E172)
 - The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).

NINLARO 3 mg hard capsule:

- The active substance is ixazomib. Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate).
- The other ingredients are:
 - In the capsule: microcrystalline cellulose, magnesium stearate and talc.
 - The capsule shell contains: gelatin, titanium dioxide (E171) and black iron oxide (E172)
 - The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).

NINLARO 4 mg hard capsule:

- The active substance is ixazomib. Each capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib citrate).
- The other ingredients are:
 - In the capsule: microcrystalline cellulose, magnesium stearate and talc.
 - The capsule shell contains: gelatin, titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172)

- The printing ink contains: shellac, propylene glycol, potassium hydroxide, and black iron oxide (E172).

What NINLARO looks like and contents of the pack

NINLARO 2.3 mg hard capsule: Light pink, size 4, marked “Takeda” on the cap and “2.3 mg” on the body with black ink.

NINLARO 3 mg hard capsule: Light grey, size 4, marked “Takeda” on the cap and “3 mg” on the body with black ink.

NINLARO 4 mg hard capsule: Light orange, size 3, marked “Takeda” on the cap and “4 mg” on the body with black ink.

Each pack contains 3 hard capsules (Three blisters sealed within the blister strip inside a wallet. Each blister contains one capsule).

Marketing Authorisation Holder

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Denmark

Manufacturer

Takeda Ireland Limited
Grange Castle Business Park
Nangor Road
Dublin 22
D22 XR57
Ireland

Takeda GmbH
Takeda (Werk Singen)
Robert Bosch Strasse 8
78224 Singen
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com

Lietuva

Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com

България

Такеда България ЕООД
Тел.: + 359 2 958 27 36
medinfoEMEA@takeda.com

Luxembourg/Luxemburg

Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com

Česká republika

Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com

Magyarország

Takeda Pharma Kft.
Tel.: +36 1 270 7030
medinfoEMEA@takeda.com

Danmark

Takeda Pharma A/S
Tlf.: +45 46 77 10 10
medinfoEMEA@takeda.com

Deutschland

Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com

Eesti

Takeda Pharma OÜ
Tel: +372 6177 669
medinfoEMEA@takeda.com

Ελλάδα

Takeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com

España

Takeda Farmacéutica España, S.A.
Tel: +34 917 90 42 22
medinfoEMEA@takeda.com

France

Takeda France SAS
Tél: + 33 1 40 67 33 00
medinfoEMEA@takeda.com

Hrvatska

Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com

Ireland

Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com

Ísland

Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com

Italia

Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com

Κύπρος

A.POTAMITIS MEDICARE LTD
Τηλ: +357 22583333
a.potamitismedicare@cytanet.com.cy

Malta

Drugsales Ltd
Tel: +356 21419070
safety@drugsalesltd.com

Nederland

Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com

Norge

Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com

Österreich

Takeda Pharma Ges.m.b.H.
Tel: +43 (0) 800-20 80 50
medinfoEMEA@takeda.com

Polska

Takeda Pharma Sp. z o.o.
Tel.: +48223062447
medinfoEMEA@takeda.com

Portugal

Takeda Farmacêuticos Portugal, Lda.
Tel: + 351 21 120 1457
medinfoEMEA@takeda.com

România

Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com

Slovenija

Takeda Pharmaceuticals farmacevtska družba d.o.o.
Tel: + 386 (0) 59 082 480
medinfoEMEA@takeda.com

Slovenská republika

Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com

Suomi/Finland

Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com

Sverige

Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com

Latvija

Takeda Latvia SIA

Tel: +371 67840082

medinfoEMEA@takeda.com

United Kingdom (Northern Ireland)

Takeda UK Ltd

Tel: +44 (0) 3333 000 181

medinfoEMEA@takeda.com

This leaflet was last revised in**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:

<https://www.ema.europa.eu>.